skip to Main Content

High-Throughput Biology and Screening drive modern drug discovery

High throughput biology and screening

Absent or malfunctioning cell signaling is responsible for disease states. Once the aberrant signal is identified, high-throughput biology and screening enable the identification of compounds capable of restoring normal cell function. This is key to ensuring that most, if not all, possible interventions are evaluated.

At IRBM, we combine compound libraries, biologically-relevant assays, and appropriate detection technologies to identify the most promising hit molecules for future optimization.

High-throughput biology and screening aid our innovative drug discovery. The quality, novelty and development potential of these chemical entities drive the success of your drug discovery projects.

We understand the importance of maximizing the probability of success at the early stages in your drug discovery program. To do so, we propose the most valid platform among a variety of tools, such as small molecules, peptides and phage display libraries.

Nowadays, it is well accepted that the diversity and quality of compound libraries are key to project success. At the same time, it is well known that the screening system must be of high identity and purity, must report for a controlled and validated number of events and must produce robust results.

High throughput biology is synonymous with diversity and speed, but it is also a measure of quality and biological/technical innovation in modern drug discovery.

IRBM High troughput biology and screening

Our capabilities

Compound libraries:

  • Small molecules (including our curated collection of over 320,000 compounds)
  • Peptides (including our phage display libraries)
  • Antibodies and large molecules (including our proprietary 1010 phage-display antibody library)

Assay development and screening systems:

  • Biochemical assays (enzymatic and binding assays with state-of-the-art technologies)
  • Cell-based assays (reporter-based, target-engagement, functional/phenotypic, disease-relevant cells)
  • Complex systems (such as our in vitro reconstituted blood-brain barrier assay)

Detection technologies:

  • State-of-the-art fluorescence (including TR-FRET and alpha) and luminescence (including split-luminescence)
  • Biophysical readouts (SPR, NMR, LC-MS)
  • qRT-PCR, FACS, high-content imaging with live module
  • Automated immunoassay (MSD, SMCxPRO, ELISA)
Back To Top